XENETIC BIOSCIENCES, INC. — Earnings

Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR

Next earnings (estimated): Wed, April 1, 2026 29 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-12-31$766K↑+18.1%
2025-09-30$1M↑+67.2%$-510K↓-16.8%-53.0%
2025-06-30$590K↓-18.8%$-689K↑+45.9%-122.8%
2025-03-31$593K↑+16.1%$-903K↑+24.4%-158.9%
2024-12-31$649K↓-3.4%
2024-09-30$614K↑+0.5%$-437K↑+58.6%-81.3%
2024-06-30$726K↑+11.6%$-1M↓-21.2%-184.1%
2024-03-31$511K↓-15.7%$-1M↓-39.5%-248.3%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q4)

Revenue
$766K
↑+18.1% +$117K YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 61 quarters

margin trajectory tells the operating-leverage story
Gross Margin↑+21.6pts
100.0%
Operating Margin↑+28.3pts
-53.0%
Net Margin↑+21.4pts
-49.7%

Go deeper